COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,778 Articles (22,946 medRxiv, 8,832 bioRxiv)

Most recent first Previous |  Page 962: Articles 9611-9620  | Next

Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant
Wolz, O.-O., Kays, S.-K., Junker, H., Koch, S. D., Mann, P., Quintini, G., von Eisenhart-Rothe, P., Oostvogels, L.
10.1101/2022.02.22.22271051 — Posted: 2022-02-24
Bacterial metatranscriptomes in wastewater can differentiate virally infected human populations
Salido, R. A., Martino, C., Karthikeyan, S., Huang, S., Rahman, G., Gonzalez, A., Zaramela, L. S., Beck, K. L., Bhute, S., Cantrell, K., Carrieri, A. P., Farmer, S., Haiminen, N., Humphrey, G., Kim, H.-C., Parida, L., Richter, R. A., Vazquez-Baeza, Y., Zengler, K., Swafford, A., Bartko, A., Knight, R.
10.1101/2022.02.23.481658 — Posted: 2022-02-24
Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., van Royen, M. E., Molenkamp, R., Oude Munnink, B., de Vries, R. D., GeurtsvanKessel, C., Smith, D. J., Koopmans, M., Rockx, B., Lamers, M. M., Fouchier, R., Haagmans, B.
10.1101/2022.02.23.481644 — Posted: 2022-02-24
Pre-clinical testing of two serologically distinct chimpanzee-origin adenovirus vectors expressing spike of SARS-CoV-2
Novikov, M., Hasanpourghadi, M., Ambrose, R., Chekaoui, A., Newman, D., Giles-Davis, W., Zhou, X., Xiang, Z., Ertl, H. C. J.
10.1101/2022.02.23.481620 — Posted: 2022-02-24
A high-throughput yeast display approach to profile pathogen proteomes for MHC-II binding
Huisman, B. D., Dai, Z., Gifford, D. K., Birnbaum, M. E.
10.1101/2022.02.22.480950 — Posted: 2022-02-24
Modeling predicts mechanisms altered by mutations of the SARS-CoV-2 delta and omicron variants
Pearson, J., Wessler, T., Chen, A., Boucher, R. C., Freeman, R., Lai, S. K., Pickles, R., Forest, M. G.
10.1101/2022.02.23.481492 — Posted: 2022-02-24
Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms
Woodcock, R. A., Bartels, L. J.
10.1101/2022.02.23.22271144 — Posted: 2022-02-24
SARS-CoV-2 RNA wastewater settled solids surveillance frequency and impact on predicted COVID-19 incidence using a distributed lag model
Schoen, M., Wolfe, M., Li, L., Duong, D., White, B., Hughes, B., Boehm, A.
10.1101/2022.02.21.22270864 — Posted: 2022-02-24
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) Network study
Sadarangani, M., Soe, P., Shulha, H., Valiquette, L., Vanderkooi, O. G., Kellner, J. D., Muller, M. P., Top, K. A., Isenor, J. E., McGeer, A., Irvine, M. A., De Serres, G., Marty, K., Bettinger, J. A., for the Canadian Immunization Research Network
10.1101/2022.02.22.22271358 — Posted: 2022-02-24
Impact of key meteorological parameters on the spread of COVID-19 in Mumbai: Correlation and Regression Analysis
Shetty, S., Gawade, A., Deolekar, S., Patil, V., Pandharkar, R., Salunkhe, U.
10.1101/2022.02.22.22271376 — Posted: 2022-02-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).